Novo Nordisk Q3 sales beat forecasts in new CEO's maiden quarter

Core Insights - Novo Nordisk reported a 15% sales growth in the third quarter, surpassing forecasts, which is a positive development for the company amid a significant restructuring effort [1] Company Performance - The sales growth of 15% indicates strong demand for Novo Nordisk's products, particularly Wegovy, which is contributing to the company's overall performance [1] - The new CEO is experiencing a boost in confidence due to the better-than-expected sales figures, which may support the ongoing restructuring initiatives [1]